E board review in Breast Cancer February 2008

Article

E board review in Breast Cancer February 2008

 

 

E-Board Review in Oncology:
Breast Cancer

The board review on breast cancer that follows is designed to help you discern the critical issues relating to the treatment of breast cancer. The subjects covered in this program represent scenarios clinicians face each day and reflect cutting-edge findings reported at major medical meetings. The hope is that the 36 questions and answers in the review will direct your focus in the ever-changing scope of options for breast cancer patients and lead to a higher quality of care and prolonged survival for them. This review should also serve as a valuable resource to help prepare you for the Medical Oncology Board Certification Examination.

After you work through the questions and answers, you can print a PDF of the entire program for future reference-instructions for doing so will appear on your screen after you complete the 36 questions.

In addition, you can earn 3 CME credits after completion of the program. Click on Earn Continuing Medical Education Credit and follow the instructions found there.

We hope you will find this review both interesting and informative-as both a resource for improving patient care and a study guide.

Editor:

Matthew J. Ellis, MB, BChir, PhD, FRCP
Director, Breast Cancer Program
Anheuser Busch Tenured
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Steven M. Sorscher, MD
Assistant Professor of Medicine
Division of Oncology
Director, Siteman Cancer Center, West Country
Washington University School of Medicine
St. Louis, Missouri

Cynthia X. Ma, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Washington University
School of Medicine
St. Louis, Missouri

 

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Ariana Pelosci
July 17th 2025
Article

Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.